## OTIS: Otis Worldwide Corporation - XLI: Industrials

### Executive Summary

No thesis match: MRS_20 0.3% below STRENGTH zone (4.0-10.0%); PEG 2.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($84.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. New England Research & Management Inc. Makes New Investment in Otis Worldwide Corporation $OTIS**
- Source: MarketBeat | 20251216T132602 | Somewhat-Bullish | Relevance: 100%
- New England Research & Management Inc. has acquired a new stake of 14,575 shares, valued at approximately $1.33 million, in Otis Worldwide Corporation during the third quarter. Otis reported strong Q3 earnings, beating estimates with $1.05 EPS and $3.69 billion revenue, and maintains a "Hold" rating from analysts with a consensus price target of $103.50. The company also announced a quarterly dividend of $0.42 per share.

**2. Q3 Earnings Highlights: Otis (NYSE:OTIS) Vs The Rest Of The General Industrial Machinery Stocks**
- Source: Finviz | 20251216T223700 | Neutral | Relevance: 96%
- This article reviews the Q3 earnings of several general industrial machinery stocks, highlighting Otis (NYSE:OTIS), Icahn Enterprises (NASDAQ:IEP), Albany (NYSE:AIN), Kadant (NYSE:KAI), and John Bean (NYSE:JBTM). It discusses their revenue performance against analysts' expectations and the subsequent stock movements, noting a strong overall Q3 for the sector. The piece also briefly touches on broader market conditions, including recent interest rate cuts and the stock market's performance in 2024.

**3. 4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease**
- Source: marketscreener.com | 20251217T181058 | Neutral | Relevance: 60%
- 4D Molecular Therapeutics reported positive interim clinical data from its 4D-710 Phase 1 AEROW trial for cystic fibrosis lung disease. The 2.5E14 vg dose cohort showed clinically meaningful activity in multiple endpoints, including ppFEV1, LCI2.5, and quality of life, confirming 2.5E14 vg as the Phase 2 dose. The company aims to complete enrollment for the Phase 2 Dose-Expansion cohort in the first half of 2026, with an update expected in the second half of 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $92 | $95 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.88M) |
| Sells | 3 ($0.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.1%)
- Blackrock Inc.: 8.2% (-1.3%)
- Alliancebernstein L.: 4.3% (-12.6%)
- State Street Corpora: 4.1% (-0.2%)
- JPMORGAN CHASE & CO: 3.9% (-32.0%)

### Key Risks

1. Long-term trend broken: trading 6.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.17 elevated, pricing in significant growth expectations. Quality metrics strong (ROA 14%). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $34.3B |
| Beta | 1.01 |
| 52W Range | $84.25 - $106.83 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.17 |
| Forward P/E | 19.5 |
| Current P/E | 21.5 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 0.3% (minimal 5-day change). Below STRENGTH zone by 3.7pp (needs >4.0% for momentum thesis). MRS_5 (-0.9%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 45. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.33% (CS: 43) | Neutral |
| RSI_14 | 45.0 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.976x | Below |
| vs SMA200 | 0.937x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $87.35
- **Stop Loss:** $84.63 (3.1% risk)
- **Target:** $90.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 261
- **Position Value:** $22,798.35
- **Portfolio %:** 22.80%
- **Risk Dollars:** $712.50
- **Risk Per Trade:** 0.71%
- **Modifiers:** L1 95% | L2 75% | Combined 0.71x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-28 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.00 | $1.05 | +4.7% |
| 2025Q2 | $1.03 | $1.05 | +2.1% |
| 2025Q1 | $0.91 | $0.92 | +1.1% |
| 2024Q4 | $0.96 | $0.93 | -2.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*